MedTrace Logo

Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

NCT00002721 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2014-05-21

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of doxorubicin plus estramustine in treating patients with metastatic recurrent prostate cancer that does not respond to hormone therapy.

Conditions

Interventions

DRUG

doxorubicin hydrochloride

DRUG

estramustine phosphate sodium

PROCEDURE

drug resistance inhibition treatment

Sponsors & Collaborators

  • University of New Mexico

    lead OTHER

Principal Investigators

  • Anthony Y. Smith, MD · University of New Mexico Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-03-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002721 on ClinicalTrials.gov